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Self-induction of rifampicin metabolism caused by dailyadministration of the drug
was studied in 7 healthy subjects. Rifampicin 600 mg was administered daily for 10
days and additional doses were administered on the 4th and 8th days after drug ad-
ministration ceased. The mean serum half-life of rifampicin decreased from 4.9 h on
the 1st day to 3.5 h on the 4th day (P<0.01), to 2.7 h on the 7th day (P<0.001),
and 2.5 h on the 10th day (P<0.001). The difference between the mean values on
the 7th and the 10th days was not significant. The mean value on the 8th day after
stopping drag administration (3.8 h), was significantly higher than that on the last day
of daily administration (P=0.02), but was still lower than that on the 1st day
(P=0.05). There was a decrease in the excretion of both rifampicin and desacetyl-
rifampicin in urine on induction, followedby a gradual return to normal when drug
administration was stopped.
Rifampicin is known to induce its
own metabolism1-4 in addition to that of
a number of other drugs5,6. Administra-
tion of this drug has been shown to be
accompanied by functional and morpho-
logical evidence of proliferation of smooth
endoplasmic reticulum and activation of
microsomal enzyme systems in the hepa-
tocyte1,7,8. Self-induction of rifampicin
metabolism could be part of the genera-
lised induction of the hepatic microsomal
enzyme system, and it should be possible
to study the phenomenon of the activa-
tion of these enzymes by following the
changes in the serum half-life of this drug.
An investigation was undertaken in
healthy subjects to determine the mini-
mum number of daily doses of rifampicin
needed to attain maximal induction of
the hepatic microsomal enzyme system,
the stability of the maximal induction so
attained with continued treatment, and
the time necessary for the induced en-
zym  levels to return to normal after
treatment is discontinued. The urinary
excretion pattern of rifampicin and its
principal metabolite, desacetylrifampicin,
was also studied. A simple method to
determine the concentrations of these two
compounds in urine involving separation
by thin-layer chromatography (TLC)
was developed, and we present here the
findings of these investigations.
Material & Methods
Design of the study : Rifampicin 600 mg
was administered daily on an empty sto-
ach to 7 healthy volunteers (mean body-
we ght : 60 kg; range 43 to 81 kg) for 10
days and then discontinued. Additional
ingle doses of the drug were then adminis-
381
382 Self-induction of rifampicin metabolism
tered on the 4th and 8th days after the
daily administration was discontinued
(i.e., on the 14th and the 18th day after
start of rifampicin administration). On
days 1, 4, 7, 10, 14 and 18, blood was
collected at 3, 4½ and 6 h and urine excre-
ted over the period 0-6 h following drug
administration (on an empty stomach)
was also collected. Concentrations of
rifampicin in serum and those of rifam-
picin and desacetylrifampicin in urine
were determined after randomising and
coding the samples.
Serum concentrations of rifampicin :
Serum concentrations of rifampicin were
determined according to the plate diffu-
sion method of Dickinson and others9,
employing a strain of Staphylococcus
aureus (subgroup I, NCTC 10702) resis-
tant to streptomycin and other antibiotics.
Rifampicin standards ranging from 0.04
to 1.28 µg/ml were set up in quadruplicate
in pooled human serum, and concentra-
tions of the drug in the samples (set up
in quadruplicate in dilutions of 1 : 10
and 1 : 20) were obtained from the re-
gression line of the log concentration of
the standard on the diameter of the zone
of inhibition.
Assuming first order kinetics, the dis-
position rate constant (K) was calculated
from the regression line of log rifampicin
concentrations in serum on time, and the
half-life (t½) was then obtained from
the equation t½ =0.693/K.
The geometric mean concentration has
been employed to describe changes in
the serum rifampicin concentrations on
the different test-days. The geometric
mean of the concentrations at 3, 4½ and
6 h was calculated for each volunteer and
the geometric mean of these mean values
was then computed for the group of 7
volunteers on each of the different test-
days.
Rif mpicin and desacetylrifampicin in
urine : The urine samples (3 ml) were
mixed with 1.5 ml of a citrate-phosphate
buffer (1.5 M, pH 7) and extracted with
3 ml of chloroform by shaking for 1 min
on a Vortex test-tube mixer. The contents
were centrifuged and the aqueous layer
w s discarded. To the chloroform extract
was then added 0.5 ml of a saturated solu-
tion of sodium chloride, the contents
shaken, centrifuged, and the aqueous
layer discarded again. The extinction of
the chloroform extract was read at 475
nm using microcells of 1 cm path-length,
and the ‘total’ rifampicin concentration
(free rifampicin plus desacetylrifampi-
cin) was calculated using rifampicin stan-
dards 10 and 50 µg/ml set up in normal
urine and processed similarly. The chloro-
form extract was then placed in a water
bath at 80-90°C and the volume concen-
trated to about 0.2 to 0.5 ml. Rifampicin
and desacetylrifampicin were separated
from each other and from the other meta-
bolites of the drug by TLC on silica gel
G. About 100 µl of the concentrated chlo-
roform extract was applied to the activa-
ted plate, and the plates were developed
with a solvent system of chloroform and
methanol (95 : 5). Portions of the adsor-
bent containing rifampicin and desace-
tylrifampicin were identified by reference
to standards, scraped off immediately,
and the compounds eluted with 1 ml of
methanol. The extinctions of the metha-
nolic extracts of rifampicin and desace-
tylrifampicin were recorded at 335 nm
in 1 cm microcells, and the respective con-
centrations calculated on the basis of the
ratio of the extinctions and the ‘total’
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rifampicin concentration determined pre-
viously after chloroform extraction.
Pure rifampicin powder was a Ciba-
Geigy product, nutrient agar and nutrient
broth were Difco products, silica-gel G
(BDH) was obtained from Glaxo Labo-
ratories (India) Ltd., and all the other
chemicals used were of analytical grade.
Desacetylrifampicin was a gift from
Dr G.A. Ellard, and the strain of Staph.
aureus (sub-group I, NCTC 10702), re-
sistant to streptomycin and other antibio-
tics, was kindly supplied by Prof. D.A.
Mitchison.
Results
Recovery of rifampicin and desacetylrifam-
picin from urine : On each of 4 occasions,
mixtures of rifampicin and desacetylri-
fampicin were set up in duplicate and in
varying proportions in concentrations
ranging from 2.5 to 100 µg/ml each. After
randomisation, the samples were pro-
cessed by the method described earlier in
this communication. The mean recovery
of ‘total’ rifampicin (rifampicin plus de-
sacetylrifampicin) was 103 per cent (range:
102-109%) following extraction of urine
with chloroform. After separation by
TLC on silica gel and elution with metha-
nol, the mean recovery of rifampicin was
100 per cent (range : 98-102%), and that
of desacetylrifampicin was 108 per cent
(range :104-115%). The co-efficient of
variation for replicate estimations ranged
from 2-17 per cent for both the com-
pounds. In a typical experiment, the Rf
values for rifampicin and desacetylrifam-
picin were 0.58 and 0.40, respectively.
Serum concentrations of rifampicin : The
mean serum concentrations of rifampicin
at 3, 4½ and 6 h, the overall mean concen-
tration (i.e., the geometric mean of the
concentrations at 3, 4½ and 6 h), and the
mean half-life of the drug on the different
test days are presented in Table I.
A progressive and significant decrease
was observed in the serum concentrations
of rifampicin when the drug was admi-
nist red daily for 7 days. The over-all
mean concentration on the 4th day was 15
per cent lower (P=0.03), and that on the
7th day was 35 per cent lower (P<0.001)
than the mean value on the 1st day.
The mean concentrations on the 7th and
the 10th days were the same, and the mean
value on the 18th day, while 21 per cent
higher than that on the 10th day (P=0.2),
was 22 per cent lower than that on the
1st day (P=0.03).
The mean serum half-life of rifampi-
cin was 29 per cent lower on the 4th day
(P<0.01), 45 per cent lower on the 7th
day (P<0.001), and 49 per cent lower
on the 10th day (P<0.001) than the mean
value on the 1st day. The difference
between the mean values on the 7th and
th  10th days was not significant. The
mean values on the 14th and 18th days
were the same, and higher than that on
the 10th day (P=0.02), but lower than
t t on the 1st day (P=0.05).
Urinary excretion of rifampicin and des-
acetylrifampicin :There was a slight but
non-significant increase in the proportion
of the dose of rifampicin excreted in the
unchanged form in urine collected over
the period 0-6 h from the 1st to the 4th
day, followed by a significant decrease
(P<0.05) when drug administration was
continued for 3 more days (Table II).
The proportion of dose excreted as des-
acetylrifampicin was, however, less on
the 4th as well as the 7th day in compari-
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Table I. Serum concentrations and half-life of rifampicin
Day
Mean serum concentrations (µg/ml)* at theOver-all mean Serum
following times (h) concentration* half-life*
(µg/ml) (h)
3 4½ 6
Table II. Excretion of rifampicin and desacetylri-
fampicin in urine collected over the period 0-6 h
(Data are mean ± SD based on estimates
for 7 volunteers)
Day
Proportion of dose (%)
excreted as the following
Rifampicin Desacetylri-
fampicin
1 7.l ± 1.6 2.8 ± 0.7
4 7.4 ± 1.1 2.3 ± 0.7
7 6.7 ± 1.0 1.7 ± 0.3
10 6.5 ± 1.6 2.0 ± 0.7
14 6.9 ± 2.0 2.4 ± 0.7
18 6.8 ± 2.0 2.4 ± 0.6
Rifampicin 600 mg was administered daily for 10
days; single doses were then administeredon th
14th and 18th days after start of treatment
son with that on the 1st day (P<0.05).
The differences between the 7th and 10th
days in the excretion of both the com-
pounds were not significant. The mean
values on the 14th and 18th days were
slightly higher than those on the 10th
day, and the excretions of both the com-
pounds on the 18th day were lower than
those on the 1st day; the differences,
however, were not significant.
The geometric mean ratios of desacety-
lrifampicin to rifampicin in urine (not
shown in the Table) were 0.35, 0.28,
0.22, 0.28, 0.31 and 0.32 respectively
on the 6 different test-days. The decrease
in the ratio from the 1st to the 7th day
and the increase from the 7th to the 18th
day were significant (P<0.01), whereas
the difference between the mean ratios on
the 1st and the 18th days was not signi-recoveries of rifampicin and desacetyl-
ficant (P>0.2). rifampicin were found to be quantitative.
Care must be taken, however, to elute the
Discussion compounds after separation from the
chromatoplate as early as possible (within
Rifampicin is metabolised in the30 min), as the colour of the spots change
body into compounds such as desacetyl-to violet on prolonged exposure to atmos-
rifampicin, rifampicin quinone, desacetyl-phere.
rifampicin quinone, 3-formylrifampicin,
3-formyldesacetylrifampicin and a fewSerum concentrations of rifampicin
others which have not been characterizedwere estimated by the plate diffusion assay
so far. These compounds are eliminatedusing Staph. aureus 
9. It has been demons-
from the system through the bile and alsotrated that the activity of desacetylrifam-
the urine. Sunahara and Nagakawale havepicin against this organism is only about
described a solvent-extraction procedure20-25 per cent of that of rifampicin
9, and
to separate rifampicin from desacetyl-that the metabolite forms only a small
rifampicin prior to their estimation inproportion (< 15%) of the total circulating
urine. Substantial interference from des-rifampicin in patients receiving this drug
12.
acetylrifampicin in the estimation of rifam-Thus, the changes observed in serum
picin was observed by us when this pro-concentrations would almost entirely re-
cedure was followed, an experience sharedflect those of unchanged rifampicin.
by McConnell and others11 We therefore Rifampicin is known to be rapidly
modified this procedure by using chloro-absorbed from the gastro-intestinal tract,
form for the initial extraction of rifampi-and peak concentrations in serum are
cin and its metabolites, and separatingat ained within 2 h after drug administra-
them from one another by TLC on silication13. Results reported in this communi-
gel. Rifampicin and desacetylrifampicincation show that the mean serum concen-
have absorption maxima at 335 and 475trations and half-life of rifampicin decrea-
nm; the other metabolites of rifampicinsed significantly during daily administra-
absorb strongly at 335 nm, but at 475 nm,tio  up to the 7th day, and there was no
the absorption is minimal10. We took further decrease when daily treatment was
advantage of these differences: the chloro-continued for 3 more days. These findings
form extract of urine was read at 475 nm,suggest that maximal induction of rifam-
thus precluding, to a great extent, thepicin metabolism,and presumably that
contributions due to compounds otherof the hepatic microsomal enzyme system,
than rifampicin and desacetylrifampicin.in general, is probably attained with about
The methanolic extract, after separation7 daily doses of this drug. These findings
of the different compounds by TLC, wasare similar to those of Acocella and others1
read at 335 nm to increase the sensitivity,who observed a decrease in serum concen-
as the molar extinction co-efficients oftrations and the half-life of rifampicin
both rifampicin and desacetylrifampicinup to the 6th day during daily administra-
were found to be higher at the shortertion of the drug and not much change
wave-length. Thus, the method describedthereafter. When the investigations were
here is specific as well as sensitive, and therepeated 4 and 8 days after daily treatment
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had been discontinued, the serum con- mg/kg body-weight) in addition to strep-
centrations and half-life showed a ten-tomycin, isoniaxid and pyraxinamide are
dency to return to normal. However, thehig ly effective, suggesting that the de-
values at 8 days after cessation oftreatmentcrease in the serum concentrations of
were still significantly lower than those on
the first day of treatment. These findings
suggest that it probably takes longer than
a week after discontinuation of treatment
for the induced enzymes to return to
normal levels.
The urinary excretion of rifampicin
and desacetylrifampicin followed a pattern
fairly similar to that of the serum half-life
of the drug. There was a slight decrease
in the excretion of both the compounds
during daily treatment, and a tendency
to return to initial levels after stopping
treatment. The decrease in the excretion of
rifampicin during treatment which has been
recorded by several other workers14-16,
is probably due to the enhanced metabo-
lism of the drug. The decrease in the ex-
cretion of desacetylrifampicin could either
be due to an increase in the biliary excre-
tion or even due to an increase of its
metabolism caused by induction due to
rifampicin. Acocella13 has shown that the
rate of transfer of desacetylrifampicin
from blood to urine decreased and that
from blood to bile increased ft r 7 days
of daily treatment. He has also suggested
the possibility of further biotransformation
of desacetylrifampicin and of an increase
in this process during daily treatment.
The decrease observed in the ratio of the
urinary excretion of rifampicin to des-
acetylrifampicin on induction is also in
accord with the findings of earlier
studies10,17,18.
Controlled clinical trials of the treat-
ment of pulmonary tuberculosis under-
taken at our Centre19,20, have demonstrated
that regimens containing rifampicm (12
rifampicin caused by daily administration
of the drug does not affect the therapeutic
effic cy of the regimens. It is possible,
however, that self-induction of its meta-
bolism exacts a therapeutic ‘penalty’, if
rifampicin is used in lower dosages.
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